ICCC - IMMUCELL CORP /DE/

8.38
-0.070   -0.835%

Share volume: 9,736
Last Updated: 05-12-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$8.45
-0.07
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 28%
Dept financing 29%
Liquidity 41%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.10%
1 Month
17.86%
3 Months
26.97%
6 Months
38.51%
1 Year
68.44%
2 Year
59.01%
Key data
Stock price
$8.38
P/E Ratio 
24.33
DAY RANGE
$8.35 - $8.56
EPS 
$0.29
52 WEEK RANGE
$4.52 - $9.08
52 WEEK CHANGE
$70.67
MARKET CAP 
56.537 M
YIELD 
N/A
SHARES OUTSTANDING 
9.046 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
-0.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$26,153
AVERAGE 30 VOLUME 
$26,121
Company detail
CEO: Michael F. Brigham
Region: US
Website: immucell.com
Employees: 70
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

ImmuCell Corporation develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine which quarter of the udder is mastitic.

Recent news